Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Berinstein, Neil L ^a   Karkada, Mohan ^b   Oza, Amit M ^c   Odunsi, Kunle ^d   Villella, Jeannine A ^e   Nemunaitis, John J ^f   Morse, Michael A ^g   Pejovic, Tanja ^h   Bentley, James ⁱ   Buyse, Marc ^j   Nigam, Rita ^b   Weir, Genevieve M ^b   MacDonald, Lisa D ^b   Quinton, Tara ^b   Rajagopalan, Rajkannan ^b   Sharp, Kendall ^b   Penwell, Andrea ^b   Sammatur, Leeladhar ^b   Burzykowski, Tomasz ^j   Stanford, Marianne M ^b   Mansour, Marc ^b   more..

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Immunovaccine Inc ^*  (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

^f Mary Crowley Cancer Research Centers   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

more..

Author keywords

cancer; DepoVax; immunotherapy; survivin; T cells

Indexed keywords

CA 125 ANTIGEN; CANCER VACCINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; OVARY CANCER; PHENOTYPE; T LYMPHOCYTE;

EID: 84940487891     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1026529     Document Type: Article

References (38)

1. L.H.Finke, K.Wentworth, B.Blumenstein, N.S.Rudolph, H.Levitsky, A.Hoos. Lessons from randomized phase III studies with active cancer immunotherapies–outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25 Suppl 2: B97-B109; PMID:17916465; http://dx.doi.org/10.1016/j.vaccine.2007.06.067
2. W.J.Lesterhuis, J.B.Haanen, C.J.Punt. Cancer immunotherapy–revisited. Nat Rev Drug Discov 2011; 10:591-600; PMID:21804596; http://dx.doi.org/10.1038/nrd3500
3. C.Kyi, M.A.Postow. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014; 588:368-76; PMID:24161671; http://dx.doi.org/10.1016/j.febslet.2013.10.015
4. M.A.Cheever, J.P.Allison, A.S.Ferris, O.J.Finn, B.M.Hastings, T.T.Hecht, I.Mellman, S.A.Prindiville, J.L.Viner, L.M.Weiner et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
5. W.T.Hwang, S.F.Adams, E.Tahirovic, I.S.Hagemann, G.Coukos. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124:192-8; PMID:22040834; http://dx.doi.org/10.1016/j.ygyno.2011.09.039
6. N.P.Restifo, L.Gattinoni. Lineage relationship of effector and memory T cells. Curr Opin Immunol 2013; 25:556-63; PMID:24148236; http://dx.doi.org/10.1016/j.coi.2013.09.003
7. J.P.Machiels, R.T.Reilly, L.A.Emens, A.M.Ercolini, R.Y.Lei, D.Weintraub, F.I.Okoye, E.M.Jaffee. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-97; PMID:11325840
8. C.M.Black, T.D.Armstrong, E.M.Jaffee. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2014; 2:307-19; PMID:24764578; http://dx.doi.org/10.1158/2326-6066.CIR-13-0145
9. M.M.Farag, R.Tedjokusumo, C.Flechtenmacher, T.Asen, W.Stremmel, M.Muller, U.Protzer, K.Weigand. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 2012; 30:6034-9; PMID:22867720; http://dx.doi.org/10.1016/j.vaccine.2012.07.057
10. S.E.Church, S.M.Jensen, P.A.Antony, N.P.Restifo, B.A.Fox. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014; 44:69-79; PMID:24114780; http://dx.doi.org/10.1002/eji.201343718
11. R.K.Sharma, E.S.Yolcu, A.K.Srivastava, H.Shirwan. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One 2013; 8: e73145; PMID:24066030; http://dx.doi.org/10.1371/journal.pone.0073145
12. F.Sallusto, A.Lanzavecchia, K.Araki, R.Ahmed. From vaccines to memory and back. Immunity 2010; 33:451-63; PMID:21029957; http://dx.doi.org/10.1016/j.immuni.2010.10.008
13. G.M.Weir, R.S.Liwski, M.Mansour. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) 2011; 3:3114-42; PMID:24212948; http://dx.doi.org/10.3390/cancers3033114
14. D.T.Le, E.M.Jaffee. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012; 72:3439-44; PMID:22761338; http://dx.doi.org/10.1158/0008-5472.CAN-11-3912
15. T.J.Waldron, J.G.Quatromoni, T.A.Karakasheva, S.Singhal, A.K.Rustgi Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology 2013; 2: e24117; PMID:23734336; http://dx.doi.org/10.4161/onci.24117
16. M.Karkada, T.Quinton, R.Blackman, M.Mansour. Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration. ISRN Oncol 2013; 2013:753427; PMID:23533812; http://dx.doi.org/10.1155/2013/753427
17. A.Lladser, C.Sanhueza, R.Kiessling, A.F.Quest. Is survivin the potential Achilles' heel of cancer? Adv Cancer Res 2011; 111:1-37; PMID:21704829; http://dx.doi.org/10.1016/B978-0-12-385524-4.00001-5
18. R.Vermeij, T.Daemen, G.H.de Bock, P.de Graeff, N.Leffers, A.Lambeck, K.A.ten Hoor, H.Hollema, A.G.van der Zee, H.W.Nijman. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010; 2010:891505; PMID:20885926; http://dx.doi.org/10.1155/2010/891505
19. N.L.Berinstein, M.Karkada, M.A.Morse, J.J.Nemunaitis, G.Chatta, H.Kaufman, K.Odunsi, R.Nigam, L.Sammatur, L.D.MacDonald et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012; 10:156; PMID:22862954; http://dx.doi.org/10.1186/1479-5876-10-156
20. M.Karkada, G.M.Weir, T.Quinton, L.Sammatur, L.D.MacDonald, A.Grant, R.Liwski, R.Juskevicius, G.Sinnathamby, R.Philip et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother 2010; 33:250-61; PMID:20445345; http://dx.doi.org/10.1097/CJI.0b013e3181c1f1e9
21. F.Ghiringhelli, C.Menard, P.E.Puig, S.Ladoire, S.Roux, F.Martin, E.Solary, A.Le Cesne, L.Zitvogel, B.Chauffert. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8
22. G.M.Weir, O.Hrytsenko, M.M.Stanford, N.L.Berinstein, M.Karkada, R.Liwski, M.Mansour, Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 2014; 3: e953407; http://dx.doi.org/10.4161/21624011.2014.953407
23. E.Sato, S.H.Olson, J.Ahn, B.Bundy, H.Nishikawa, F.Qian, A.A.Jungbluth, D.Frosina, S.Gnjatic, C.Ambrosone et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
24. N.Obermajer, R.Muthuswamy, K.Odunsi, R.P.Edwards, P.Kalinski. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463-70; PMID:22025564; http://dx.doi.org/10.1158/0008-5472.CAN-11-2449
25. J.C.Becker, M.H.Andersen, V.Hofmeister-Muller, M.Wobser, L.Frey, C.Sandig, S.Walter, H.Singh-Jasuja, E.Kampgen, A.Opitz et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61:2091-103; PMID:22565484; http://dx.doi.org/10.1007/s00262-012-1266-9
26. V.Lennerz, S.Gross, E.Gallerani, C.Sessa, N.Mach, S.Boehm, D.Hess, L.von Boehmer, A.Knuth, A.F.Ochsenbein et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014; 63:381-94; PMID:24487961; http://dx.doi.org/10.1007/s00262-013-1516-5
27. L.Gattinoni, C.A.Klebanoff, D.C.Palmer, C.Wrzesinski, K.Kerstann, Z.Yu, S.E.Finkelstein, M.R.Theoret, S.A.Rosenberg, N.P.Restifo. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115:1616-26; PMID:15931392; http://dx.doi.org/10.1172/JCI24480
28. C.A.Klebanoff, L.Gattinoni, P.Torabi-Parizi, K.Kerstann, A.R.Cardones, S.E.Finkelstein, D.C.Palmer, P.A.Antony, S.T.Hwang, S.A.Rosenberg et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005; 102:9571-6; PMID:15980149; http://dx.doi.org/10.1073/pnas.0503726102
29. C.E.Gomez, J.L.Najera, B.Perdiguero, J.Garcia-Arriaza, C.O.Sorzano, V.Jimenez, R.Gonzalez-Sanz, J.L.Jimenez, M.A.Munoz-Fernandez, J.C.Lopez Bernaldo de Quiros et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011; 85:11468-78; PMID:21865377; http://dx.doi.org/10.1128/JVI.05165-11
30. Y.Hailemichael, Z.Dai, N.Jaffarzad, Y.Ye, M.A.Medina, X.F.Huang, S.M.Dorta-Estremera, N.R.Greeley, G.Nitti, W.Peng et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465-72; PMID:23455713; http://dx.doi.org/10.1038/nm.3105
31. E.P.Salerno, S.M.Shea, W.C.Olson, G.R.Petroni, M.E.Smolkin, C.McSkimming, K.A.Chianese-Bullock, C.L.Slingluff, Jr. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother 2013; 62:1149-59; PMID:23657629; http://dx.doi.org/10.1007/s00262-013-1435-5
32. K.D.Brewer, K.Lake, N.Pelot, M.M.Stanford, D.R.DeBay, A.Penwell, G.M.Weir, M.Karkada, M.Mansour, C.V.Bowen. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine 2014; 32:6956-62; PMID:25444822; http://dx.doi.org/10.1016/j.vaccine.2014.10.058
33. C.L.SlingluffJr, G.Yamshchikov, P.Neese, H.Galavotti, S.Eastham, V.H.Engelhard, D.Kittlesen, D.Deacon, S.Hibbitts, W.W.Grosh et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7:3012-24; PMID:11595689
34. A.Galecki, T.Burzykowski. Linear Mixed-Effect Models Using R. Vol. 10. 2013, New York: Springer.
35. A.Galecki. General class of covariance structures for two or more repeated factors in longitudinal data analysis. Commun Statist Theory Methods 1994; 23:3105-3119; http://dx.doi.org/10.1080/03610929408831436
36. M.Kenward, R.J.Small. Small sample inference for fixed ffects from restricted maximum likelihood. Biometrics 1997; 53:983-997; PMID:9333350; http://dx.doi.org/10.2307/2533558
37. A.Dmitrienko, A.C.Tamhane, F.Bretz,, Multiple testing problems in pharamceutical statistics. 2010, Boca Raton: Chapman & Hall/ CRC Press.
38. E.Ellebaek, L.Engell-Boerregaard, T.Z.Iversen, T.M.Froesig, S.Munir, S.R.Hadrup, M.H.Andersen, I.M.Svane. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 2012; 61:1791-804; PMID:22426890; http://dx.doi.org/10.1007/s00262-012-1242-4